Glucagon like Peptide 1 News and Research

RSS
Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study

Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patients

Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patients

SELECT trial shows semaglutide reduces kidney decline in obese patients

SELECT trial shows semaglutide reduces kidney decline in obese patients

Sharp uptick in youth using wegovy and ozempic, study reports

Sharp uptick in youth using wegovy and ozempic, study reports

Key studies on GLP-1 drugs, alpha-gal syndrome, and liver disease medications to be presented at DDW 2024

Key studies on GLP-1 drugs, alpha-gal syndrome, and liver disease medications to be presented at DDW 2024

From research to practice: Closing the divide in obesity management

From research to practice: Closing the divide in obesity management

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Sustainable weight loss with personalized semaglutide dosing

Sustainable weight loss with personalized semaglutide dosing

Aerobic exercise proves most effective for combating obesity-related inflammation

Aerobic exercise proves most effective for combating obesity-related inflammation

The complex relationship between obesity and male reproductive function

The complex relationship between obesity and male reproductive function

Treating early-stage heart failure in diabetic patients: Insights from ARISE-HF trial

Treating early-stage heart failure in diabetic patients: Insights from ARISE-HF trial

Weight loss drugs associated with increased risk of aspiration pneumonia following endoscopy

Weight loss drugs associated with increased risk of aspiration pneumonia following endoscopy

AI-based analysis uncovers two plant extracts with potential as GLP-1 agonist weight loss pills

AI-based analysis uncovers two plant extracts with potential as GLP-1 agonist weight loss pills

New research sheds light on how GLP-1 obesity drugs may change food cravings

New research sheds light on how GLP-1 obesity drugs may change food cravings

Diabetes drug dulaglutide may reduce symptoms of depression

Diabetes drug dulaglutide may reduce symptoms of depression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.